GlobeNewswire: InflaRx N.V. Contains the last 10 of 107 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:24:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850106/0/en/InflaRx-Reports-Full-Year-2023-Results-and-Announces-INF904-Development-Plans.html?f=22&fvtc=4&fvtv=46782InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans2024-03-21T11:00:00Z<![CDATA[JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial and operating results for the year ended December 31, 2023, and provided a comprehensive strategic update on its future development and operational plans.]]>https://www.globenewswire.com/news-release/2024/03/19/2848459/0/en/InflaRx-to-Announce-Development-Plans-for-INF904-and-2023-Financial-Results-on-March-21-2024.html?f=22&fvtc=4&fvtv=46782InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 20242024-03-19T11:30:00Z<![CDATA[JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.]]>https://www.globenewswire.com/news-release/2024/02/22/2833581/0/en/InflaRx-Appoints-Jan-Medina-as-Head-of-Investor-Relations.html?f=22&fvtc=4&fvtv=46782InflaRx Appoints Jan Medina as Head of Investor Relations2024-02-22T12:30:00Z<![CDATA[JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.]]>https://www.globenewswire.com/news-release/2024/01/25/2816626/0/en/InflaRx-Announces-Initiation-of-its-Commitment-Program-for-GOHIBIC-vilobelimab-to-Help-Broaden-Access-for-Eligible-Patients.html?f=22&fvtc=4&fvtv=46782InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients2024-01-25T12:30:00Z<![CDATA[ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit.]]>https://www.globenewswire.com/news-release/2024/01/04/2803830/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Multiple-Ascending-Dose-MAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html?f=22&fvtc=4&fvtv=46782InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF9042024-01-04T12:00:00Z<![CDATA[JENA, Germany, Jan. 04, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today topline results from the multiple ascending dose (MAD) part of its randomized, double-blind, placebo-controlled Phase I trial for INF904, an orally administered low molecular weight C5aR inhibitor. The pharmacokinetic (PK) and pharmacodynamic (PD) parameters confirm the favorable data InflaRx reported recently from the single ascending dose (SAD) part of the study, which provides support for the best-in-class potential of this drug candidate. INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.]]>https://www.globenewswire.com/news-release/2023/11/06/2773976/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-III-Trial-with-Vilobelimab-in-Pyoderma-Gangrenosum.html?f=22&fvtc=4&fvtv=46782InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum2023-11-06T12:30:00Z<![CDATA[JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its Phase III study investigating the efficacy and safety of vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease characterized by destructive, painful cutaneous ulcers.]]>https://www.globenewswire.com/news-release/2023/11/01/2771018/0/en/InflaRx-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=46782InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-01T11:30:00Z<![CDATA[JENA, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results for the three and nine months ended September 30, 2023, and provided an operating update.]]>https://www.globenewswire.com/news-release/2023/09/11/2740655/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Single-Ascending-Dose-SAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html?f=22&fvtc=4&fvtv=46782InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF9042023-09-11T11:00:00Z<![CDATA[JENA, Germany, Sept. 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today its topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904. In the SAD part of the study, INF904 demonstrated an excellent safety and tolerability profile as well as a very favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile, confirming INF904´s best-in-class potential.]]>https://www.globenewswire.com/news-release/2023/08/30/2734224/0/en/InflaRx-s-Marketing-Authorization-Application-MAA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency-EMA.html?f=22&fvtc=4&fvtv=46782InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)2023-08-30T11:30:00Z<![CDATA[JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the Company has submitted a Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) and that the European Medicines Agency (EMA) has validated the MAA. This means that the application is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure, which applies to all 27 member states of the European Union (EU).]]>https://www.globenewswire.com/news-release/2023/08/10/2722561/0/en/InflaRx-Reports-Second-Quarter-2023-Financial-Results-Operating-Update.html?f=22&fvtc=4&fvtv=46782InflaRx Reports Second Quarter 2023 Financial Results & Operating Update2023-08-10T11:30:00Z<![CDATA[• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States]]>